RBC Capital has upgraded its outlook for Biocryst Pharmaceuticals (BCRX) from Sector Perform to Outperform. According to Fintel, the average one-year price target for Biocryst Pharmaceuticals is $15.40, with a high forecast of $31.50. This represents a 124.85% increase from the latest closing price of $6.85. The projected annual revenue for Biocryst Pharmaceuticals is $363 million, an 18.45% increase. The projected annual non-GAAP EPS is -0.86. There are currently 431 funds or institutions reporting positions in Biocryst Pharmaceuticals, a decrease of 8.49% in the last quarter. The put/call ratio of BCRX is 0.16, indicating a bullish outlook. Among the major shareholders, Baker Bros. Advisors holds 6.71% ownership of the company, Avoro Capital Advisors holds 6.36% ownership with an increase of 13.56%, the XBI – SPDR(R) S&P(R) Biotech ETF holds 4.44% ownership with an increase of 9.58%, and the VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 3.09% ownership with an increase of 1.76%. Assenagon Asset Management holds 2.81% ownership with an increase of 6.85%. Biocryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases. They have several ongoing development programs, including oral Factor D inhibitor BCX9930, ALK-2 inhibitor BCX9250, and potential treatments for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in several countries. Fintel is a comprehensive investing research platform that provides data on fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, insider trading, and more.
By James Taylor
A writer and finance enthusiast who loves diving into the exciting world of stocks, commodities, forex, and crypto. I'm all about making the financial markets less intimidating and more accessible, so I write engaging content that simplifies complex concepts and shares practical investment strategies. Whether you're a seasoned investor or just getting started, I've got your back! But hey, life isn't all about work, right? On weekends, you'll find me hanging out and having a blast with my awesome friends and family. We love bonding over shared interests, trying out new adventures, and simply enjoying each other's company. Striking that balance between work and play is super important to me, because what's the point of success if you can't share it with the people you love? So, if you're up for some financial market insights and a good dose of weekend fun, stick around! Together, we'll navigate the money world and make the most of our time off. Let's learn, grow, and create memories along the way!
Related Posts
